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Objectives: To determine the publicly funded health care costs associated 
with breast cancer (BC) by stage of disease in the first two years following diag-
nosis. MethOds: Incident cases of female invasive BC (ICD-9 174.x) diagnosed 
between 2005 and 2009 were extracted from the provincial cancer registry and linked 
by their encrypted health card number to administrative datasets. The type and 
usage of publicly funded health care services used were stratified by disease stage 
over the first two years following diagnosis. BC cases were matched to controls 
(women without cancer). Overall average costs (2008$CAN) and costs per resource 
per BC case were compared to a control group. The attributable cost for the two-year 
time horizon was determined. Results: There were 39,655 BC cases and 190,520 
controls in our cohort study. The average age was 61.1 years old and 60.9 years old, 
respectively. Of the BC cases with staging information, the majority of cases were 
Stage I (34.4%) and Stage II (31.8%). Eight percent of the entire cohort died within 
the first two years of diagnosis. The overall mean cost per BC case from a public 
payer perspective in the first two years following diagnosis was $41,686 based on the 
study cohort of 39,655 BC cases. The mean cost increased by stage: Stage I ($29,938), 
Stage II ($46,893), Stage III ($65,369) and IV ($66,627). When compared to controls, 
the net cost for BC cases was $31,732. Cost drivers for the entire cohort were can-
cer clinic visits, physician billing and inpatient hospitalizations. cOnclusiOns: 
Costs increased by stage of disease. Cost drivers were identified and a net cost was 
calculcated. This data will allow for planning and decision making around limited 
health care resources.
PCN169
TreaTmeNT PaTTerNs amoNg PaTieNTs wiTh BreasT CaNCer: Does 
iNsuraNCe sTaTus maTTer?
Jiao X., Mu G., Cai Y.
IMS Health, Plymouth Meeting, PA, USA
Objectives: Mixed results have been reported on the associations between insur-
ance coverage and cancer treatment, probably due to different population involved. 
This study was conducted to investigate treatment patterns by insurance status 
in patients with breast cancer using a large national database. MethOds: The 
National Cancer Database (NCDB) was used to examine the initial treatment after 
diagnosis. Patients were classified into the early stage group (stage 0-2) and the 
advanced stage group (stage 3-4). Logistic regressions were used to estimate the 
Odds ratios (ORs, with confidence intervals [95% CIs]) of receiving surgery, hor-
mone therapy, and chemotherapy by insurance status. Results: A total of 2,317,286 
patients with breast cancer were retrieved from the database during the study 
period (2000-2011). Patients with private insurance, Medicare, Medicaid or no insur-
ance accounted for 53.8%, 35.5%, 4.8%, and 2.2% respectively. Compared with the 
uninsured, patients with private insurance, Medicare, or Medicaid were more likely 
to receive surgery in both early stage group (OR 2.97, [2.83-3.11], OR 2.00, [1.90-2.09], 
OR 1.58, [1.49-1.67] respectively) and advanced stage group (OR 2.89, [2.78-3.01], OR 
1.45, [1.39-1.51], OR 1.60, [1.53-1.68] respectively). In the early stage group, patients 
with private insurance and Medicare were more likely to undergo partial mastec-
tomy than the uninsured (OR 1.40, [1.37-1.43], OR 1.36, [1.33-1.39]), while patients 
with Medicaid had similar utilization of partial mastectomy as the uninsured 
(OR 1.02, [1.0-1.05]). In the advanced stage group, patients with private insurance, 
Medicare, or Medicaid were more likely to receive hormone therapy (OR 1.54, [1.48-
1.60], OR 1.68, [1.61-1.74], OR 1.20, [1.15-1.26]) than the uninsured. Patients with 
private insurance and Medicaid were also more likely to receive chemotherapy (OR 
1.67, [1.60-1.74], OR 1.39, [1.32-1.46]), while patients with Medicare were less likely 
to receive chemotherapy (OR 0.36, [0.34- 0.37]) than the uninsured. cOnclusiOns: 
Insurance status is associated with different treatment patterns. It may have an 
impact on clinical management of patients with breast cancer.
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Objectives: The study aims to systematically review the efficacy, safety and 
cost-effectiveness of trastuzumab in metastatic gastric cancer treatment in 
China. MethOds: A systematic review method was performed. We collected both 
national and international clinical, cost-effectiveness and disease burden stud-
ies mainly from database of Pubmed, MEDLINE, CNKI, etc. And health insurance 
status of trastuzumab in China was also collected. Results: With inclusion and 
exclusion criteria, there were 8 clinical studies, 2 cost-effectiveness study and 19 
disease burden studies finally recruited for the analysis. Clinical results showed 
that trastuzumab in combination with chemotherapy were effective and well toler-
ated in target population. In ToGA, the only phase III randomized controlled trial, 
compared with chemotherapy alone, trastuzumab plus chemotherapy substantially 
improved overall survival (13.8 vs. 11.1 months) and progression-free survival (6.7 
vs. 5.5 months). One cost effectiveness study revealed that from the perspective of 
UK NHS, ICER of trastuzumab plus chemotherapy among IHC3+ or IHC2+/FISH+ 
patients was 66,982-71,637 pounds per QALY, compared with chemotherapy alone. 
Gastric cancer had brought a heavy disease burden to China. The DALY lost from 
gastric cancer was 1.48-5.03 per thousand patients and average hospitalization 
expenditure per patient was rising. By the first half year of 2013, there were more 
than 6 provinces and cities in China providing public reimbursement for trastu-
zumab, but only 2 for gastric cancer indication. cOnclusiOns: Trastuzumab with 
chemotherapy can be considered as a new standard option for HER2-positive meta-
static gastric cancer patients. However, more evidences on efficacy, safety and cost 
effectiveness of trastuzumab are still needed to support local public decision making 
on health insurance benefits update in China.
the DDD results indicated small declines in medication adherence for cancer sur-
vivors relative to beneficiaries without a cancer diagnosis in all three drug classes 
(3 to 5 percentage points), whereas longer term cancer survivors had much better 
adherence to all three drug classes (10 to 12 percentage points higher) relative to 
beneficiaries with cancer who had a poor prognosis. cOnclusiOns: A diagnosis of 
cancer among Medicare beneficiaries with diabetes significantly reduces adherence 
with evidence-based medications recommended in diabetes treatment guidelines.
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Objectives: To examine total health care-expenditures in the initial phase-of-care 
among Medicare beneficiaries with colorectal cancer (CRC) from a rural setting, 
and compare them with “national” estimates. MethOds: A population-based ret-
rospective cohort-study was conducted on fee-for-service Medicare beneficiaries 
aged ≥ 66 years diagnosed with CRC between 2003-2006 identified from the West 
Virginia Cancer Registry (WVCR)-Medicare linked database (n= 2,114). Similarly, a 
comparative cohort was identified from Surveillance, Epidemiology, and End Results 
(SEER)-Medicare (n= 38,172). Medicare claim payment-amounts were used to cal-
culate total average health care, inpatient, outpatient, physician-visits, and other 
health care-utilization expenditures. To control for geographic variation in cost-of-
living across the different counties, health care-expenditures were expressed using 
county-specific cost-of-living indices (COLI). Results: After COLI-adjustment, the 
average total health care expenditures in the initial phase-of-CRC care for those 
from the WVCR-Medicare linked-database were estimated at $46,644. The average 
total health care and inpatient expenditures in initial phase-of-care were found to 
be lower (5% and 4%, respectively) for those from WVCR-Medicare as compared to 
those from SEER-Medicare. However, they had a higher co-morbidity burden, and 
significantly higher (45%) outpatient expenditures as compared to their “national” 
counterparts. The outpatient expenditures were higher specifically for beneficiaries 
with chronic-conditions, which have a higher prevalence in the WVCR-Medicare 
group as compared to those from SEER-Medicare. Further, the differences in total 
health care-expenditures between beneficiaries from WVCR-Medicare and SEER-
Medicare reduced from $2,282 to $898, and remained no longer significant in a 
multivariable setting after controlling for receipt of minimally-appropriate CRC 
treatment (MACT) and presence of chronic-conditions. cOnclusiOns: This study 
highlights the importance of providing preventive health care services and better 
co-management of CRC and chronic-conditions, to control the higher outpatient 
expenditures among beneficiaries with CRC from a rural population. This study 
also showed that the differences in total health care-expenditures between rural 
and “national” population are likely to be partially explained by the receipt of MACT 
and comorbidity-burden.
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Objectives: To examine colorectal cancer (CRC) treatment patterns in the ini-
tial phase-of-care, the extent of receipt of minimally-appropriate CRC-treatment 
(MACT), the associated survival in a three-year period following a CRC-diagnosis 
in Medicare beneficiaries diagnosed with CRC from a rural setting, and to com-
pare these findings with “national” estimates. MethOds: A population-based 
retrospective cohort-study was conducted with data from fee-for-service Medicare 
beneficiaries aged ≥ 66 years diagnosed with CRC between 2003-2006 identified from 
the West Virginia Cancer Registry (WVCR)-Medicare linked database (n= 2,119). A 
comparative “national” cohort was identified from Surveillance, Epidemiology, and 
End Results (SEER)-Medicare (n= 38,168). CRC-treatment received was ascertained 
from beneficiaries’ Medicare claims by following them for 12-months from their 
CRC-diagnosis date or until death. Receipt of MACT was defined based on National 
Cancer Institute CRC-treatment guidelines. All-cause and CRC-specific mortality 
in the 36-month period following CRC-diagnosis were examined after accounting 
for selection bias using inverse probability treatment weights. Results: Although 
a higher proportion of beneficiaries from WVCR-Medicare were diagnosed in the 
earlier stages of CRC (when it can still be treated effectively) as compared to their 
SEER-Medicare counterparts, they had poorer CRC-survivorship with adjusted haz-
ards ratio (AHR)= 1.26;95%CI= [1.20,1.32]. This poorer survivorship may be due to 
a lower-likelihood (adjusted odds ratios (AOR)= 0.85;95%CI= [0.76,0.96]) of benefi-
ciaries from WVCR-Medicare of receiving MACT as compared to their “national” 
counterparts. Differences in usage of CRC-surgery, chemotherapy and radiation 
were also observed in the two populations. Those from WVCR-Medicare were less 
likely to receive any type of CRC-surgery with AOR= 0.82;95%CI= [0.73,0.93]. cOnc
lusiOns: This study highlights the need for an increased emphasis on adoption 
and adherence to accepted surgical and adjuvant CRC-treatment guidelines, and 
improving access to CRC-care for those from rural-settings. Further research needs 
to be conducted to determine if similar rural-urban differences in receipt of MACT 
exist in the elderly in other rural-areas of the nation.
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